NCT02247401View on ClinicalTrials.gov

Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

PHASE3CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

November 4, 2014

Primary Completion Date

August 1, 2016

Study Completion Date

August 1, 2016

Conditions
HCVHepatitis C InfectionGenotype 4
Interventions
DRUG

2 DAA

ABT-450/r/ABT-267 tablets

DRUG

RBV

Ribavirin tablets

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT02247401 - Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt | Biotech Hunter | Biotech Hunter